SecBot SecBot

AZN

ASTRAZENECA PLC
NYSE· Pharmaceutical Preparations· Inc. X0· CIK 0000901832 Biotech & Drug Discovery
$184.20 −0.25 (−0.14%)
Nov 16 4:00 PM ET · prev $184.45
Market cap
$286.0B
Mega cap
Consensus
Buy
82% Buy or better · 34 analysts
Median target
$210.00
+14% · range $158.00–240.00
1 year
+3.0%
from $178.80 · Nov 17
30 days
+11.4%
from $165.41
52-week range
$155.62–209.48
−12% from high · low Aug 4
Avg volume 20D
2.96M
shares / day
Short interest
3.03M
≈0.2% of shares · −7.7%
Days to cover
1.0
at average volume
Insider net
−$2.2M
1 buyer · 1 seller · 12 mo
New fund stakes
10
Q2 2026 13F · 5 exits
Reddit crowd
50°
Neutral · 2 mentions this week
SecBot read BULLISH 36 reports · 90 days
Balance 2 bearish · 15 bullish · 1 mixed · 18 neutral oldest → newest, height = score
Avg score ·High conf. 31/36
Strongest🔒 Fresh report (last 24h), subscribers only

Price

Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).

  • May 20 ▼ 1 insider sell $2.2M at $185.78
  • Jun 29 to Jul 9 3 court rulings: Factor Bioscience Inc. v. Cellectis, Inc., Cellectis S.A…; AstraZeneca v. Murrill and 1 more
  • Jun 30 ▲ 10 funds open new positions (13F)
  • Jul 23 to Aug 3 3 court rulings: Dressen v. AstraZeneca AB, et al; ASTRAZENECA PHARMACEUTICALS LP v. FREY et al and 1 more
  • Aug 8 ▲ 1 insider buy $3.2K at $160.57
  • Aug 24 CICC initiates
  • Sep 30 ▼ Short interest jumps 25.4% to 2.62M
  • Oct 2 ASTRAZENECA PHARMACEUTICALS LP et al v. SANDOZ INC. et al
  • Oct 13 to Oct 15 2 court rulings: Johnson v. ASTRAZENECA PHARMACEUTICALS LP et al; Shareholder Representative Services, LLC v. Alexion…
  • Oct 15 ▼ Short interest jumps 25.4% to 3.28M
  • Oct 22 ▲ AstraZeneca announced that the FDA granted accelerated approval for…
  • Nov 13 ▲ Drug approval: EMA: Human medicines European public assessment report (EP…
  • Nov 16 New report: subscribers see the details Unlock
  • Nov 16 New catalyst: subscribers see the details Unlock

Signal stack

Where each data set points today.

  • InsidersBEARISH

    1 insider bought $3.2K at an average $160.57. 1 insider sold $2.2M. Price is 15% above their cost.

  • InstitutionsBULLISH

    Q2 2026: 53 added (10 new), 27 trimmed or exited. Largest new: Dimensional Fund Advisors $551.0M, Caisse De Depot Et Placement Du Quebec $273.9M.

  • AnalystsBULLISH

    28 of 34 rate it Buy or better. Median target $210.00 (+14%).

  • Short sellersSTEADY

    Short interest −7.7% to 3.03M shares. 1.0 days to cover, ≈0.2% of shares.

  • TrendUPTREND

    9% above its 50-day average.

  • SocialQUIET

    Crowd 50° (neutral) this week from 2 mentions: 0 bullish, 0 bearish. No setup is alerting.

Who's buying

13F· Q2 2026
10
new positions
5
exits
$1.6B
in new stakes
FundMoveSharesValue
NORGES BANKDOUBLED33,864,172$6.3B
CAUSEWAY CAPITAL MANAGEMENT LLCADD9,357,390$1.8B
Rathbones Group PLCDOUBLED7,979,150$1.5B
CITIGROUP INCADD4,895,753$916.2M
Boston PartnersADD3,177,627$597.4M
DIMENSIONAL FUND ADVISORS LPNEW2,904,886$551.0M
RAYMOND JAMES FINANCIAL INCADD2,409,624$456.9M
JONES FINANCIAL COMPANIES LLLPADD1,670,876$314.8M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

34 analysts
Buy 82% rate it Buy or better
Strong Buy12Buy16Hold6Sell0Strong Sell0
12-month targets · 12 analysts

Price is inside the target range. Median implies +14%.Targets as of Nov 16, 2026.

Recent actions
DateFirmActionRating
Aug 24, 2026CICC
INITIATE
INITIATEOutperform
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
8 drugs tracked · Drug pipeline →
Recent
Nov 15, 2026
Trial readout
🔒 Fresh data, subscribers only
Nov 15, 2026
Trial readout
🔒 Fresh data, subscribers only
Nov 16, 2026
Clinical Trial
🔒 Fresh data, subscribers only
Nov 16, 2026
Clinical Trial
🔒 Fresh data, subscribers only
Nov 13, 2026
Drug approval
EMA: Human medicines European public assessment report (EPAR): Baxfendy, baxdrostat, Status: Opinion
Human medicines European public assessment report (EPAR): Baxfendy, baxdrostat, Status: Opinion

Insider ledger

Form 4
$3.2K
bought · 1 insider
$2.2M
sold · 1 insider
+14.7%
vs their $160.57 cost
DateInsiderTypeValue
Nov 6, 2026
Sharma Mani
See remarks
Nov 6, 2026
AWARD$186.24
Oct 6, 2026
Sharma Mani
See remarks
Oct 6, 2026
AWARD$319.60
Sep 8, 2026
Sharma Mani
See Remarks
Sep 8, 2026
AWARD$162.60
Aug 8, 2026
Sharma Mani
See Remarks
Aug 8, 2026
BUY$3.2K
Aug 6, 2026
Sharma Mani
SVP, Group Controller
Aug 6, 2026
AWARD$326.68
Jul 6, 2026
Sharma Mani
See Remarks
Jul 6, 2026
AWARD$380.86
Jun 8, 2026
Sharma Mani
See Remarks
Jun 8, 2026
AWARD$179.75
May 20, 2026
Sharma Mani
See Remarks
May 20, 2026
SELL$2.2M

Earnings setup

Estimates

Revision history: 🔒 Fresh data, subscribers only

PeriodEPS est.Range30D rev.Revenue
Current Q🔒 Fresh data, subscribers only
Next QNoneNoneNo data$16.0B
Current FY🔒 Fresh data, subscribers only
Next FY🔒 Fresh data, subscribers only

Washington

Corporate Lobbying

16 lobbying filings and 3 bills this company lobbies on, with spend, stage and how each bill touches it, are for subscribers.

Subscribe for Full Access

Short side

FINRA· Oct 30, 2026
3,032,797
shares short
-7.7%
vs prior settlement
1.0
days to cover
≈0.2%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow, newest first.
Nov 16, 2026 SEC
🔒 Fresh report (last 24h), subscribers only
Nov 16, 2026 SEC
🔒 Fresh report (last 24h), subscribers only
Nov 16, 2026 SEC
🔒 Fresh report (last 24h), subscribers only
Nov 15, 2026 Clinical trial readout
🔒 Fresh data, subscribers only
Nov 6, 2026 Insider
Sharma Mani was granted 1 shares
See remarks @ $186.24 ($186.24)
Oct 23, 2026 Event
SYMBICORT AEROSPHERE
Supplemental Approval · Labeling · AEROSOL, METERED
Oct 15, 2026 Event
Shareholder Representative Services, LLC v. Alexion Pharmaceuticals Inc.
Court ruling (delch), Docket: C.A. No. 2020-1069-MTZ
Oct 6, 2026 Insider
Sharma Mani was granted 2 shares
See remarks @ $159.80 ($319.60)
Reddit Mentions per day, 14 days
Crowd this week 50° Neutral 0 bullish · 0 bearish
Mentions, 7 days 2 1 in posts · 1 in comments
Recent posts
Recent comments
All social signals and their track records

SecBot reports

77 filings · 38 bullish · 4 bearish · 4 mixed · 31 neutral
All AZN filing & press-release reports (77)